Ligand Pharmaceuticals (LGND) Peer Comparison
$307.82
$-6.96
(-2.21%)
As on 22-Oct-2026 16:00EDT
Market cap
$5,892 Mln
Revenue (TTM)
$291 Mln
P/E Ratio
31.1
P/B Ratio
6.2
Div. Yield
0 %
Edit
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
5,892 | 11,908 | 12,979 | 11,757 | 8,801 |
Revenue ($ Mln) |
291 | 831 | 713 | 5,020 | 432 |
Net Profit ($ Mln) |
197.22 | 54.90 | -696.24 | -199.00 | -136.72 |
Net Margin (%) |
67.88 | 6.61 | -97.64 | -3.96 | -31.66 |
RoE (%) |
19.87 | 8.11 | -- | -3.03 | -30.32 |
Price to Earnings |
31.14 | 244.80 | -- | -- | -- |
Price-To-Book |
6.16 | 18.00 | 123.68 | 1.71 | 23.58 |
Income Statement ($ Mln)
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
290.54 | 830.81 | 713.07 | 5,020.00 | 431.80 |
|
Cost of Revenue
|
4.12 | 14.09 | 47.45 | 2,380.00 | 207.41 |
|
Gross Profit
|
261.50 | 748.43 | 473.81 | 2,050.00 | 191.00 |
|
Operating Expenses
|
185.49 | 810.32 | 1,209.09 | 2,178.00 | 362.16 |
|
Operating Profit (EBIT)
|
100.93 | 6.41 | -543.47 | 462.00 | -137.77 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
237.96 | 26.37 | -706.17 | -166.00 | -135.85 |
|
Provision for Tax
|
40.74 | -35.26 | -7.73 | 33.00 | 0.24 |
|
Profit after Tax (Net Income)
|
197.22 | 54.90 | -696.24 | -199.00 | -136.72 |
|
Minority Interest
|
0.00 | 0.00 | 10.15 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
967.52 | 705.78 | -2,515.22 | 6,588.00 | 445.74 |
|
Minority Interest
|
0.00 | 0.00 | 10.15 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
1,171.62 | 29.12 | 2,832.54 | 5,121.00 | 106.44 |
|
Current Liabilities
|
46.74 | 153.80 | 890.65 | 1,852.00 | 120.26 |
|
Total Liabilities
|
1,560.64 | 836.65 | 936.03 | 13,358.00 | 641.86 |
Assets ($ Mln)
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
728.76 | 449.03 | 124.16 | 9,764.00 | 351.14 |
|
Current Assets
|
1,457.12 | 439.68 | 1,093.14 | 3,797.00 | 321.30 |
|
Total Assets
|
1,560.64 | 836.65 | 936.03 | 13,358.00 | 641.86 |
|
Total Debt*
|
1,131.45 | 9.42 | 2,493.78 | 3,918.00 | 93.59 |
|
Net Current Assets
|
1,410.38 | 285.87 | 202.49 | 1,945.00 | 201.04 |
Cashflow ($ Mln)
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
49.36 | 142.00 | -445.91 | 560.00 | -47.63 |
|
Cash Flow from Investing Activities
|
-377.32 | 69.76 | -24.49 | -279.00 | -24.76 |
|
Cash from Financing Activities
|
428.22 | -220.37 | 359.29 | -275.00 | 28.54 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.79 | 14.87 | -159.44 | -2.21 | -13.30 |
|
ROE (%)
|
19.87 | 8.11 | 41.15 | -3.03 | -30.32 |
|
ROA (%)
|
12.15 | 5.52 | -41.39 | -1.30 | -17.95 |
|
EBIT Margin (%)
|
82.50 | 3.17 | -86.43 | 1.61 | -30.84 |
|
Net Margin (%)
|
67.88 | 6.61 | -97.64 | -3.96 | -31.66 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
54.89 | 16.02 | 202.39 | 11.95 | 19.19 |
|
EBIT Growth (%)
|
396.48 | -79.11 | 5.05 | -90.61 | -57.38 |
|
Net Profit Growth (%)
|
359.97 | -58.66 | 10.33 | -145.85 | -60.49 |
|
EPS Growth (%)
|
337.28 | -62.44 | 12.58 | -146.42 | -52.59 |
|
Book Value Growth (%)
|
6.56 | 12.98 | -36.90 | -3.87 | -8.64 |
Valuation Ratios
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
32.11 | 41.86 | -20.69 | -48.47 | -21.89 |
|
Price / Book Value
|
3.93 | 6.44 | -7.27 | 1.72 | 3.60 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.27 | 55.67 | -25.47 | 21.77 | -30.81 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.16 | 0.00 | -0.77 | 0.58 | 0.00 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | -0.22 | 0.01 | 0.02 |
|
Current Ratio
|
31.18 | 2.86 | 1.23 | 2.05 | 2.67 |
|
Quick Ratio
|
30.96 | 2.77 | 1.17 | 1.10 | 2.38 |
|
Interest Coverage
|
39.44 | -- | -6.86 | 0.36 | -- |
Operating Efficiency Ratios
| Ligand Pharmaceuticals (LGND) | Corcept Therapeutics (CORT) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
24.07 | 9.26 | 35.69 | 22.95 | 15.23 |
|
Asset Turnover
|
0.18 | 0.84 | 0.42 | 0.33 | 0.57 |
|
Receivable days
|
70.50 | 28.27 | 52.44 | 70.73 | 44.72 |
|
Inventory Days
|
644.28 | 355.76 | 172.81 | 226.89 | 51.56 |
|
Payable days
|
234.84 | 785.55 | 296.14 | 45.50 | 12.52 |
|
Cash Conversion Cycle
|
479.94 | -401.52 | -70.89 | 252.12 | 83.76 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
